![Photo of APOL1 Study participant enrolling](/sites/default/files/styles/freeform_scaled/public/2024-07/APOL1%20study%20enrollment%20%281%29.jpg?itok=Ti56Q1dS)
Using data from community studies based at Duke Kannapolis, researchers found that COVID vaccination was not associated with new onset of APOL1-related kidney disease in African American adults who were at high risk for the condition.
The findings were published June 20 by Kidney International Reports. The authors concluded that validation of their result in larger cohorts would further support the renal safety of COVID vaccine in people with APOL1 high-risk genotype.
Duke Kannapolis — CTSI's research site at the North Carolina Research Campus — is part of the new Center for Precision Health. The COVID vaccination research used data from the MURDOCK Study, led by Svati H. Shah, MD, MHS, and the Duke APOL1 Study, led by Opeyemi A. Olabisi, MD. Shah directs Duke Kannapolis and the Center for Precision Health and is principal investigator for the MURDOCK Study.